Interim Report for the period January – March 2025

Leqembi approved in the EU and billion-dollar license agreement with Bristol Myers Squibb came into effect Events during the first quarter 2025 · FDA approved less frequent IV maintenance dosing of Leqembi® for the treatment of early Alzheimer’s disease and accepted the Biologics License Application (BLA) for subcutaneous maintenance dosing of Leqembi in the US · Leqembi sales during BioArctic’s partner Eisai’s fiscal year 2024 (Apr-24 – Mar-25) exceeded EUR 200 M, resulting in a EUR 10 M milestone payment to BioArctic · The license agreement with Bristol Myers Squibb came